Dr. Damian O’Connell heads EDDC as Chief Executive Officer (CEO). He also holds additional positions including Adjunct Professor at the University College Cork, Ireland, Member of the Advisory Board SingHealth Investigational Medicine Unit in Singapore, and a board member of the INFANT research centre in Ireland. In addition, he is a member of several medical societies. These include the British Pharmacological Society, the Drug Safety Executive Council (DSEC), the American Society for Clinical Pharmacology and Therapeutics, the American College of Clinical Pharmacology, the American Society of Pharmacometrics, the Irish Association of Pharmacologists, the Irish Cardiac Society, and the British Hypertension Society.
Having started his career in the Industry in 1998, Dr. O’Connell has previously has held senior positions within Bayer, Pfizer Research & Development, Parke Davis, Elan Pharmaceuticals & Neurex. Apart from his extensive experience in the Industry, he has also held positions in academia. Dr. O’Connell has been a Medical Faculty member of The University of Virginia Health Sciences Centre, and Professor in the Clinical Pharmacology & Therapeutics Department at University College Cork, Ireland.
Dr. Damian O’Connell received both his M.D. and Ph.D. from the National University of Ireland. He is also a Fellow of both The Royal Society of Medicine and The Royal Academy of Medicine (Ireland).